TNF inhibitor combined with methotrexate versus single DMARD (methotrexate): The effect of TNF inhibitor was highly significant (Z = 10.84).

<p>The 13 TNF inhibitor studies showed no significant heterogeneity (I² = 42%, p = 0.06). The borderline heterogeneity was due to two golimumab studies (GoBefore, GoForward) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0106408#pone.0106408-Emery2" target="_blank">[46]</a>. The exclusion of these, did, however, not change the overall result (−0.33 SMD (CI: −0.39, −0.27)).